Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $88.43 Consensus PT from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have received a consensus rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $87.83.

GPCR has been the subject of a number of research analyst reports. JMP Securities dropped their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, Morgan Stanley began coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sandia Investment Management LP acquired a new position in Structure Therapeutics during the 2nd quarter worth approximately $39,000. Quarry LP acquired a new position in shares of Structure Therapeutics during the second quarter worth $79,000. Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics in the fourth quarter valued at $139,000. ADAR1 Capital Management LLC acquired a new stake in Structure Therapeutics during the 4th quarter valued at $163,000. Finally, Mather Group LLC. purchased a new stake in Structure Therapeutics during the 2nd quarter worth $214,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $40.38 on Tuesday. The company has a 50-day simple moving average of $38.73 and a 200-day simple moving average of $40.10. The company has a market cap of $1.88 billion, a PE ratio of -52.44 and a beta of -3.53. Structure Therapeutics has a 12 month low of $26.61 and a 12 month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, analysts anticipate that Structure Therapeutics will post -0.86 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.